

Oyebamiji AK, Semire B. Studies of anti-hypertensive activity of 1,4-dihydropyridine derivatives: combinations of DFT-QSAR and docking approaches. *Bull. Pharm. Res.* 2016; 6(3):105-13.

References (31):

1. ALJumali MHA. Synthesis, characterization, docking studies and bio-efficacy evaluation of novel 1, 4-dihydropyridine derivatives. *Int. J. Sci. Res.* 2015;4(12):74-6.
<http://worldwidejournals.in/ojs/index.php/ijsr/article/view/3109/3123>
2. Balasubramanian R, Vijaya Gopal R. Design and in silico analysis of ring-A monosubstituted chalcones as potential anti-inflammatory agents. *Bull. Pharm. Res.* 2012;2(2):70-7.
<https://www.appconnect.in/app/journalUploads/dp-5-4.pdf>
3. Becke AD. Density-functional thermochemistry. III. The role of exact exchange. *J. Chem. Phys.* 1993;98(7):5648-52.
[http://140.123.79.88/~frenins/image/PCr\(py\)3\(CO\)n\(NO+\)3-n/%A4%E5%C4m/hybrid_DFT.pdf](http://140.123.79.88/~frenins/image/PCr(py)3(CO)n(NO+)3-n/%A4%E5%C4m/hybrid_DFT.pdf)
4. Biovia. Wateridge vista drive, San Diego, CA 92121, USA. 2005.
5. Dewar MJS, Zoebisch EG, Healy EF, Stewart JJP. Development and use of quantum mechanical molecular models. 76. AM1: A new general purpose quantum mechanical molecular model. *J. Am. Chem. Soc.* 1985;107(13):3902-9.
<http://pubs.acs.org/doi/abs/10.1021/ja00299a024>
6. Eroğlu E, Türkmen H, Güler S, Palaz S and Oltulu O. A DFT-based QSARs study of acetazolamide/sulfanilamide derivatives with carbonic anhydrase (CA-II) isozyme inhibitory activity. *Int. J. Mol. Sci.* 2007;8(2):145-55.
<http://www.mdpi.com/1422-0067/8/2/145>
7. Goldman BB, Wipke WT. QSD quadratic shape descriptors. 2. Molecular docking using quadratic shape descriptors (QSDock). *Proteins* 2000;38(1):79-94.
<https://www.ncbi.nlm.nih.gov/pubmed/10651041>
8. Goodarzi M, Dejaegher B, Vander Heyden Y. Features selection methods in QSAR studies. *J. AOAC Int.* 2012;95(3):636-51.
<https://www.ncbi.nlm.nih.gov/pubmed/22816254>
9. Havas S, Fujimoto W, Close N, McCarter R, Keller J, Sherwin R. The NHLBI workshop on hypertension in Hispanic Americans, Native Americans, and Asian/Pacific Islander Americans. *Public Health Rep.* 1996;111(5):451-8.
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1381791>

10. Karelson, M. *Molecular Descriptors in QSAR/QSPR*. John Wiley & Sons, New York: 2000.
11. Lee C, Yang W, Parr RG. Development of the Colle-Salvetti correlation-energy formula into a functional of the electron density. *Phys. Rev. B Condens. Matter* 1988;37(2):785-9.
<https://www.ncbi.nlm.nih.gov/pubmed/9944570>
12. Lip GYH, Beevers DG. Calcium channel blockers in hypertension: the debate reawakens. *J. Hum. Hypertens.* 2001;15(2):85-7.
<https://www.ncbi.nlm.nih.gov/pubmed/11317185>
13. Liu J, Prakash O, Cai M, Gong Y-X, Huang Y, Wen L, Wen JJ, Huang J-K, Krishnamoorth R. Solution structure and backbone dynamics of recombinant cucurbita maxima trypsin inhibitor-V determined by NMR spectroscopy. *Biochemistry* 1996;35(5):1516-24.
<http://pubs.acs.org/doi/abs/10.1021/bi952466d>
14. Meng EC, Shoichet BK, Kuntz ID. Automated docking with grid-based energy evaluation. *J. Comp. Chem.* 1992;13(4):505-24.
<http://onlinelibrary.wiley.com/doi/10.1002/jcc.540130412/abstract>
15. Miri R, Javidnia K, Mirkhani H, Kazemi F, Hemmateenejad B, Edraki N, Mehdipour AR. Synthesis and in vitro dual calcium channel antagonist-agonist activity of some 1, 4-Dihydro-2, 6-dimethyl-3-nitro and cyano-4-(1-methyl-5-nitro-1*H*-imidazol-2-yl)-5-pyridine carboxylates. *Daru J. Pharm. Sci.* 2008;16(4):263-70.
<http://daru.tums.ac.ir/index.php/daru/article/view/510/399>
16. Morris GM, Lim-Wilby M. Molecular docking. *Methods Mol. Biol.* 2008;443:365-82.
<https://www.ncbi.nlm.nih.gov/pubmed/18446297>
17. Nantasenamat C, Isarankura-Na-Ayudhya C, Naenna T, Prachayasittikul V. A practical overview of quantitative structure-activity relationship. *Excli J.* 2009;8:74-88.
http://www.excli.de/vol8/prachayasittikul_04_2009/prachayasittikul_050509_proof.pdf
18. Ogah OS, Rayner BL. Recent advances in hypertension in sub-Saharan Africa. *Heart* 2013;99(19):1390-7.
<https://www.ncbi.nlm.nih.gov/pubmed/23708775>
19. Olson KR. *Poisoning and Drug Overdose*. 6th edition, McGraw-Hill Education, Columbus, OH: 2011.
20. Oyebamiji A and Semire B. Studies of 1, 4-Dihydropyridine derivatives for anti-breast cancer (MCF-7) activities: combinations of DFT-QSAR and docking methods. *New York Sci. J.* 2016;9(6):58-66.
http://www.sciencepub.net/newyork/ny090616/10_30806nys090616_58_66.pdf
21. Ponce YM, Garit JAC, Torrens F, Zaldivar VR, Castro EA. Atom, atom-type, and total linear indices of the "molecular pseudograph's atom adjacency matrix": application to QSPR/QSAR studies of organic compounds. *Molecules* 2004;9(12):1100-23.

22. Sharma V, Kumar V. Efficient way of drug designing: a comprehensive review on computational techniques. *Bull. Pharm. Res.* 2014;4(3):118-23.
<http://journal.appconnect.in/wp-content/uploads/2015/01/Reprintbpr1011.pdf>
23. Sharma V, Wakode SR, Lather V, Mathur R, Fernandes MX. Structure based rational drug design of selective phosphodiesterase-4 ligands as anti-inflammatory molecules. *Bull. Pharm. Res.* 2011;1(2):33-40.
<https://www.appconnect.in/wp-content/uploads/2012/01/ReprintBPR020.pdf>
24. Singh PP, Srivastava HK, Pasha FA. DFT-based QSAR study of testosterone and its derivatives. *Bioorg. Med. Chem.* 2004;12(1):171-7.
<https://www.ncbi.nlm.nih.gov/pubmed/14697782>
25. Stewart JJP. Optimization of parameters for semiempirical methods II. Applications. *J. Comp. Chem.* 1989;10(2):221-64.
<http://onlinelibrary.wiley.com/doi/10.1002/jcc.540100209/abstract>
26. Rani S, Ajeet, Kumar A. Designing of sulfanilamide/sulfacetamide derivatives as human topoisomerase II inhibitor: A docking approach. *Am. J. Pharmacol. Sci.* 2014;2(2):42-6.
<http://pubs.sciepub.com/ajps/2/2/3/>
27. Todeschini R, Consonni V. Handbook of Molecular Descriptors, Wiley-VCH Verlag, Weinheim, Germany: 2000.
<http://onlinelibrary.wiley.com/doi/10.1002/9783527613106.fmatter/pdf>
28. Tropsha A. Best practices for QSAR model development, validation and exploitation. *Mol. Inform.* 2010;29(6-7):476-88.
<http://onlinelibrary.wiley.com/doi/10.1002/minf.201000061/abstract>
29. Wold S, Eriksson L. Statistical validation of QSAR results. In Waterbeemd, Han van de. Chemometric methods in molecular design. Weinheim, VCH, Germany: 1995; 309-18.
<http://onlinelibrary.wiley.com/doi/10.1002/9783527615452.fmatter/pdf>
30. Whitworth JA. 2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension. *J. Hypertens.* 2003;21(11): 1983-92.
31. Zhang L, Wan J, Yang G. A DFT-based QSARs study of protoporphyrinogen oxidase inhibitors: phenyl triazolinones. *Bioorg. Med. Chem.* 2004;12(23):6183-91.
<https://www.ncbi.nlm.nih.gov/pubmed/15519162>